Biovie (BIVI) Accounts Payables (2013 - 2026)
Biovie (BIVI) posted Accounts Payables of $1.6 million for Q1 2026, down 44.88% sequentially from $2.9 million in Q4 2025, and down 34.92% YoY from $2.5 million in Q1 2025.
Biovie (BIVI) Accounts Payables (2013 - 2026) Analysis & Trends
Biovie has reported Accounts Payables for 14 years, with the latest figure at $1.6 million in Q1 2026.
- Quarterly Accounts Payables fell 34.92% year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (down 34.92% YoY) and the FY2025 annual result came in at $2.2 million, down 38.66% from the prior year.
- Accounts Payables fell to $1.6 million in Q1 2026 per BIVI's latest filing, from $2.9 million in the prior quarter.
- Over five years, Accounts Payables peaked at $4.8 million in Q1 2023 and troughed at $1.2 million in Q1 2022.
- A 5-year average of $2.8 million and a median of $2.7 million in 2023 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2023 and 2024: Accounts Payables jumped 301.15% in 2023, then tumbled 61.68% in 2024.
- Over 5 years, Accounts Payables stood at $3.2 million in 2022, then rose by 11.18% to $3.6 million in 2023, then sank by 61.68% to $1.4 million in 2024, then surged by 111.45% to $2.9 million in 2025, then slumped by 44.88% to $1.6 million in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $1.6 million, $2.9 million, and $1.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Biovie | 14.17 Mn | 14.17 Mn | - | 3.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.70 Mn |
| Mar 31, 2026 | 1.61 Mn |
| Dec 31, 2025 | 2.92 Mn |
| Sep 30, 2025 | 1.57 Mn |
| Jun 30, 2025 | 2.20 Mn |
| Mar 31, 2025 | 2.48 Mn |
| Dec 31, 2024 | 1.38 Mn |
| Sep 30, 2024 | 3.45 Mn |
| Jun 30, 2024 | 3.59 Mn |
| Mar 31, 2024 | 4.41 Mn |
| Dec 31, 2023 | 3.61 Mn |
| Sep 30, 2023 | 2.71 Mn |
| Jun 30, 2023 | 3.48 Mn |
| Mar 31, 2023 | 4.84 Mn |
| Dec 31, 2022 | 3.25 Mn |
| Sep 30, 2022 | 2.62 Mn |
| Jun 30, 2022 | 2.44 Mn |
| Mar 31, 2022 | 1.21 Mn |
| Dec 31, 2021 | 1.66 Mn |
| Sep 30, 2021 | 679,393.00 |